Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study
Restricted accessResearch articleFirst published online March, 2007
Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study
Gadolinium (Gd) enhancement of lesions indicates inflammatory lesion activity in multiple sclerosis (MS). The question arises whether early inflammatory lesion activity – measured sensitively using triple dose Gd – is related to the future clinical course, or to the development of brain atrophy that is thought to reflect the underlying pathological progression of the disease. In this study, 26 patients with early relapsing-remitting (RR) MS (median disease duration: 1.7 years) were followed up over two years. Associations were explored between their levels of Gd-lesion enhancement in the first six months and later clinical (Expanded Disability Status Scale (EDSS) and MS Functional Composite Score (MSFC)) and magnetic resonance imaging (MRI) (brain volume, T2 and T1 lesion volumes) measures. The extent of Gd-enhancement in the first six months correlated weakly with concurrent relapses (P = 0.041), but there was no consistent correlation with clinical and MRI outcomes at two years. More prolonged follow-up is warranted to clarify the relationship between early inflammatory lesions and long-term clinical course. Multiple Sclerosis 2007; 13: 178–185. http://msj.sagepub.com
BrückW, BitschA, KolendaH, BrückY, StiefelM, LassmannH. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.Ann Neurol1997; 42: 783–93.
2.
KatzD, TaubenbergerJK, CannellaB, McFarlinDE, RaineCS, McFarlandHF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.Ann Neurol1993; 34: 661–69.
3.
FilippiM. Enhanced magnetic resonance imaging in multiple sclerosis.Mult Scler2000; 6: 320–26.
4.
MillerDH, RudgeP, JohnsonG, KendallBE, MacManusDG, MoseleyIF. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.Brain1988; 111: 927–39.
5.
MillerDH, BarkhofF, BerryI, KapposL, ScottiG, ThompsonAJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.J Neurol Neurosurg Psychiatry1991; 54: 683–88.
ThompsonAJ, MillerDH, YoulB, MacManusD, MooreS, KingsleyD. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration.Neurology1992; 42: 60–63.
8.
McFarlandHF, FrankJA, AlbertPS, SmithME, MartinR, HarrisJO. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.Ann Neurol1992; 32: 758–66.
9.
SmithME, StoneLA, AlbertPS, FrankJA, MartinR, ArmstrongM. Clinical worsening in multiple sclerosis is associated with increased frequency and area of Gadopentetate Dimeglumine-enhancing imaging lesions.Ann Neurol1993; 33: 480–89.
10.
KapposL, MoeriD, RadueEW, SchoetzauA, SchweikertK, BarkhofF. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis.Lancet1999; 353: 964–69.
11.
LosseffNA, MillerDH, KiddD, ThompsonAJ. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis - preliminary results.Mult Scler2001; 7: 23–25.
12.
KhourySJ, GuttmannCRG, OravEJ, HoholMJ, AhnSS, HsuL. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.Neurology1994; 44: 2120–24.
13.
StoneLA, SmithME, AlbertPS, BashCN, MaloniH, FrankJA. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age.Neurology1995; 45: 1122–26.
TrappBD, PetersonJ, RansohoffRM, RudickR, MorkS, BoL. Axonal transection in the lesions of multiple sclerosis.N Engl J Med1998; 338: 278–85.
16.
KuhlmannT, LingfeldG, BitschA, SchuchardtJ, BrückW. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.Brain2002; 125: 2202–12.
17.
ZivadinovR, ZorzonM. Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature.J Neuroimaging2002; 12: 302–309.
18.
SaindaneAM, GeY, UdupaJK, BabbJS, MannonLJ, GrossmanRI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS.Neurology2000; 55: 61–65.
19.
FilippiM, RovarisM, CapraR, GasperiniC, YousryTA, SormaniMP. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.Brain1998; 121: 2011–20.
20.
SilverNC, GoodCD, BarkerGJ, MacManusDG, ThompsonAJ, MoseleyIF. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.Brain1997; 120: 1149–61.
21.
RovarisM, MastronardoG, PrandiniF, BastianelloS, ComiG, FilippiM. Short-term evaluation of new multiple sclerosis lesions enhancing on standard dose and triple dose gadolinium-enhanced MRI scans.J Neurol Sci1999; 164: 148–52.
22.
van WaesbergheJH, CastelijnsJA, RoserW, SilverN, YousryT, LycklamaA, NijeholtGJ. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions.AJNR Am J Neuroradiol1997; 18: 1279–85.
23.
PoserCM, PatyDW, ScheinbergL, McDonaldWI, DavisFA, EbersGC. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.Ann Neurol1983; 13: 227–31.
24.
LublinFD, ReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey.Neurology1996; 46: 907–11.
25.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology1983; 33: 1444–52.
26.
CutterGR, BaierML, RudickRA, CookfairDL, FischerJS, PetkauJ. Development of a multiple sclerosis functional composite as a clinical trial outcome measure.Brain1999; 122: 871–82.
27.
FilippiM, Gawne-CainML, GasperiniC, van WaesbergheJH, GrimaudJ, BarkhofF. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.Neurology1998; 50: 238–44.
28.
TiberioM, ChardDT, AltmannDR, DaviesG, GriffinCM, RashidW. Grey and white matter volume changes in early RRMS: a two-year longitudinal study.Neurology2005; 64: 1001–1007.
29.
ChardDT, GriffinCM, ParkerGJM, KapoorR, ThompsonAJ, MillerDH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis.Brain2002; 125: 327–37.
30.
ConfavreuxC, VukusicS, AdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.Brain2003; 126: 770–82.
31.
BrexPA, CiccarelliO, O'RiordanJI, SailerM, ThompsonAJ, MillerDH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.N Engl J Med2002; 346: 156–64.
32.
WeinshenkerBG, BassB, RiceGP, NoseworthyJ, CarriereW, BaskervilleJ. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.Brain1989; 112: 1419–28.
33.
Katz-LevyY, NevilleKL, PadillaJ, RahbeS, BegolkaWS, GirvinAM. Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice.J Immunol2000; 165: 5304–14.
34.
FilippiM, RoccaMA, RizzoG, HorsfieldMA, RovarisM, MinicucciL. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium.Neurology1998; 50: 1289–93.
35.
ThorpeJW, KiddD, MoseleyIF, KendallBE, ThompsonAJ, MacManusDG. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.Neurology1996; 46: 373–78.
36.
SilverNC, GoodCD, SormaniMP, MacManusDG, ThompsonAJ, FilippiM. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis.J Neurol2001; 248: 215–24.
37.
CohenJA, CutterGR, FischerJS, GoodmanAD, HeidenreichFR, JakAJ. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.Arch Neurol2001; 58: 961–67.
38.
SolariA, RadiceD, ManneschiL, MottiL, MontanariE. The multiple sclerosis functional composite: different practice effects in the three test components.J Neurol Sci2005; 228: 71–74.
LassmannH. Axonal injury in multiple sclerosis.J Neurol NeurosurgPsychiatry2003; 74: 695–97.
41.
AllenIV, GloverG, AndersonR. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis.Acta Neuropathol (Berl)1981; suppl IV: 176–78.
42.
EvangelouN, EsiriMM, SmithS, PalaceJ, MatthewsPM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.Ann Neurol2000; 47: 391–95.
43.
PetersonJW, BoL, MonkS, ChangA, TrappBD. Transected neuritis, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.Ann Neurol2001; 50: 389–400.
44.
MorgenK, JeffriesNO, StoneR, MartinR, RichertND, FrankJA. Ring-enhancement in multiple sclerosis: marker of disease severity.Mult Scler2001; 7: 167–71.
45.
RoviraA, AlonsoJ, CucurellaG, NosC, TintoreM, PedrazaS. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization transfer MR images.AJNR Am J Neuroradiol1999; 20: 1939–45.
46.
LucchinettiCF. The MS Lesion Project: merging of minds and matter.Mult Scler2003; 9 (Suppl 1): 47.
